Pharmaceutical Executive-03-01-2022

Pressed Into Action: Measuring Pharma’s Reputation Reversal

March 08, 2022

Back Page

Study analyzes mainstream media coverage of the industry before and after the COVID-19 lockdown.

Biopharma in 2021: Big Gains, Volatile Values

March 08, 2022

Features

Full-year business review of pharma and biotech sectors reveals strong momentum in advancing novel science and treatments, but likely foretells continued stock instability in near-to-medium terms.

The Resilience of R&D: Pharma Posted Record Output in 2021

March 08, 2022

Features

Despite disruption from the COVID-19 pandemic still in full swing, life sciences innovation activity remained undeterred, a recent report from the IQVIA Institute for Human Data Science finds—outlining the key factors driving record-breaking growth.

A Complex Patent & Pricing Picture: Regulating Psychedelics More of a Journey Than a Trip

March 08, 2022

Features

Pharma and legal experts weigh in on the rush to secure intellectual property around psychedelic medicines, the value imperative that should govern pricing strategies, and the likely long-haul battle for more widespread decriminalization of these drugs.

New Age of Psychedelics

March 08, 2022

Features

A look at the renewed efforts of biopharma companies in exploring age-old substances to treat mental health conditions and more, minus the negative effects.

Roads Less Traveled

March 08, 2022

Executive Profile

After helping lead Novo Nordisk on a transformational journey from a troubled 2016 to double-digit growth in 2021, Doug Langa, Executive Vice President, Head of North America Operations and President of Novo Nordisk, Inc., is calling on his experience of taking the less conventional and sometimes unexpected routes to success to lead Novo Nordisk into new territory.